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OBJECTIVES The aim of this study was to evaluate the feasibility and safety of carotid artery stenting (CAS)
with a filter protection system.
BACKGROUND Neurologic events linked to the embolization of particulate matter to the cerebral circulation
may complicate CAS. Strategies designed to capture embolic particles during carotid
intervention are being evaluated for their efficacy in reducing the risk of these events.
METHODS Between September 1999 and July 2001, a total of 162 patients (164 hemispheres) underwent
CAS with filter protection (NeuroShield, MedNova Ltd., Galway, Ireland) according to
prospective protocols evaluating the filter system at three institutions.
RESULTS Angiographic success was achieved in 162 of the procedures (99%) and filter placement was
successful in 154 (94%) procedures. Carotid access was unsuccessful in two cases (1%) and
filter placement in eight cases (5%). Of the latter, five procedures were completed with no
protection and three were completed using alternative protection devices. On an intention-
to-treat basis, the overall combined 30-day rate of all-stroke and death was 2% (four events:
two minor strokes and two deaths). This includes one minor stroke in a patient with failed
filter placement and CAS completed without protection. There was one cardiac arrhythmic
death and one death from hyperperfusion-related intracerebral hemorrhage. There were no
major embolic strokes.
CONCLUSIONS Carotid artery stenting with filter protection is technically feasible and safe. Early clinical
outcomes appear to be favorable and need to be confirmed in a larger comparative
study. (J Am Coll Cardiol 2002;39:841–6) © 2002 by the American College of Cardiology
Foundation
The efficacy of carotid endarterectomy (CEA) in preventing
stroke is dependent on the perioperative incidence of stroke
and death (1). Accordingly, the American Heart Associa-
tion has set guidelines for the performance of CEA. On the
basis of these guidelines, CEA should only be performed if
the combined rate of perioperative stroke and death can be
kept 6% in symptomatic patients and 3% in asymptom-
atic patients with severe extracranial carotid stenoses (1).
Extrapolating these guidelines to the performance of carotid
artery stenting (CAS), experienced groups have reported
outcomes that are consistent with these recommendations
(2–4). However, despite advanced stenting techniques,
neurologic events may still complicate CAS and remain an
obstacle to its widespread acceptance. Obstructive carotid
artery lesions are known to contain friable thrombotic and
atherosclerotic components that have the potential to em-
bolize during intervention and may be responsible for the
majority of the neurologic events during CAS. This has
been demonstrated in an ex vivo human carotid artery model
by Ohki et al. (5), as well as by several transcranial Doppler
(TCD) studies during CAS (6). A number of “distal
protection” strategies, designed to capture embolic debris
released during carotid intervention, are currently being
evaluated for their efficacy in minimizing the risk of embolic
neurologic events. One such strategy is the placement of a
temporary intravascular filter that captures embolic matter
in the distal internal carotid artery (ICA) during interven-
tion (6). The aim of this study was to prospectively
investigate CAS with a filter protection system.
MATERIALS AND METHODS
Between September 1999 and July 2001, a total of 162
patients (164 hemispheres, 164 procedures) underwent elec-
tive CAS with a filter protection system (NeuroShield,
MedNova Ltd., Galway, Ireland) according to prospective
protocols examining the feasibility and safety of the system
during CAS at three institutions: New York, 64 cases
(40%); Milan, 50 cases (30%); and Sheffield, 50 cases (30%).
The enrollment criteria were identical and included patients
with symptomatic or asymptomatic extracranial ICA steno-
sis of 50% and 70% (diameter obstruction) respectively,
as determined by carotid angiography. Additionally, all
enrolled patients satisfied the following criteria: 1) age 18
years; 2) ability to understand the procedure and sign a
written consent; 3) a negative pregnancy test in women of
childbearing age; 4) suitable lesion for treatment with
angioplasty and stenting (based on the absence of significant
calcification, thrombus and extremely tortuous anatomy); 5)
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sufficient space for filter placement distal to the lesion; and
6) ICA diameter 4 mm but 6 mm.
Exclusion criteria included: 1) breastfeeding women; 2)
stroke within seven days before the procedure; 3) National
Institute of Health Stroke Score (NIHSS) of 15 within
seven days before the procedure or baseline major ipsilateral
stroke that is likely to confound the determination of the
study clinical end points; 4) more than one ipsilateral carotid
lesion requiring treatment; 5) the presence of a cardiac
source of embolus (such as atrial fibrillation); 6) the presence
of known intracranial tumors or vascular malformation; 7)
renal insufficiency (creatinine 2.5 mg/dl); and 8) comor-
bidity with a life expectancy of 1 year.
The primary end points included: 1) technical success
(angiographic and device success) and 2) procedural and
30-day incidence of minor stroke, major stroke, myocardial
infarction and death.
All procedures were performed according to the guide-
lines of the Institutional Review Board or the local medical
ethics committee. All patients signed a written consent. All
patients had a complete neurologic evaluation performed by
a neurologist that included an assessment of the NIHSS
before and within 24 h after the procedure. Additionally (at
Lenox Hill), clinical events were adjudicated, based on
patient chart review, by an independent clinical events
committee that was selected to include a neuroradiologist, a
neurologist and a surgeon.
Clinical and procedural data were documented by a
dedicated research coordinator using a special case report
form and were entered into a computerized database.
Thirty-day follow-up that included queries regarding po-
tential neurologic events was completed on each patient.
Imaging studies were utilized in determining occurrences of
end points whenever necessary.
Patients were premedicated with clopidogrel (Plavix,
Pfizer Inc., New York, New York) 75 mg once a day and
aspirin 100 to 325 mg twice a day for a minimum of seven
days before the procedure. Clopidogrel was continued for 30
days after CAS (14 days in Sheffield) and aspirin was
continued indefinitely. All carotid stenting procedures were
performed using a standard technique as previously de-
scribed (7). A 7F/90-cm long guiding sheath (Shuttle, Cook
Inc., Indianapolis, Indiana) was used to access the carotid
artery. A single bolus of intravenous heparin (5,000 U or 70
U/kg) was administered at the beginning of the procedure.
The filter system was employed according to the manufac-
turer’s instructions as described later. Glycoprotein IIb/IIIa
antagonists were not utilized.
Device description. The Generation-II NeuroShield
(MedNova Ltd.) is a temporary intravascular filtration
system designed to capture atheromatous material released
during the carotid interventional procedures (Fig. 1). The
system is composed of three major components: 1) the filter
guidewire, 2) a delivery catheter and 3) a retrieval catheter.
Abbreviations and Acronyms
CAS  carotid artery stenting
CEA  carotid endarterectomy
CREST  Carotid Revascularization Endarterectomy vs.
Stenting Trial
ECA  external carotid artery
ICA  internal carotid artery
NIHSS  National Institutes of Health Stroke Score
TCD  transcranial Doppler
Figure 1. Application of the NeuroShield filter system during carotid artery stenting. The filter is mounted on a filter wire that is used to cross the lesion
and deliver interventional balloon and stent catheters. ICA  internal carotid artery.
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The filter assembly is located at the distal end of 0.014-inch
guidewire that is used to cross the lesion (Fig. 1). The
filtration element, made of polyurethane, has four proximal
entry ports and multiple distal perfusion pores (100 to
150 m) that allow blood flow to the cerebral circulation
(Fig. 2). The filter is available in diameters of 4 to 6 mm and
is sized to the selected distal ICA segment (1:1). A
preshaped Nitinol expansion system assists in filter deploy-
ment and apposition to the arterial wall.
Filter deployment and retrieval are performed using
dedicated catheters. At the commencement of an interven-
tional procedure, the filter system is loaded into the delivery
catheter. The system is then advanced through the guiding
sheath and across the target lesion into the distal ICA. The
delivery catheter is withdrawn and, as it is withdrawn, the
filter is deployed. After the delivery catheter is removed, an
angiogram is obtained to document blood flow through the
filter and document device placement distal to the target
lesion (Fig. 2C). The filter guidewire is used to deliver the
balloon and stent delivery catheters. Following the comple-
tion of the procedure, the filter assembly is recovered using
the retrieval catheter. This is advanced over the guidewire
and through the stented lesion, then further over the
deployed filter assembly. As the retrieval catheter distal pod
contacts the proximal edge of the filter assembly, the Nitinol
expanders collapse and the filter assembly is rewrapped, fully
contained within the retrieval catheter. The entire device is
then removed from the patient with the captured emboli
contained in the filtration element. In cases where the filter
delivery catheter system is unable to cross the lesion on the
initial attempt because of lesion severity or vessel tortuous-
ity, a gentle predilation (using a 2-mm balloon) or a
side-wire “buddy wire” was used to facilitate the system
advancement (Fig. 2).
DEFINITIONS
Technical success. Device success: successful placement and
retrieval of the NeuroShield filter device. Angiographic
success: successful stent deployment resulting in 30% re-
sidual diameter stenosis.
Stroke. Minor stroke: an arterio-occlusive brain infarction
characterized by the sudden onset of a neurologic deficit
that persists for 24 h. In all cases, patients must be
nondisabled. Major stroke: an arterio-occlusive brain infarc-
tion characterized by the sudden onset of a neurologic
deficit (NIHSS 9) persisting for a minimum of 30 days.
Procedural event. A procedural event is the occurrence of
any clinical event during the procedure, from the time
femoral arterial access is obtained and until vascular access
site hemostasis is successfully achieved.
30-day outcome. The 30-day outcome was the composite
incidence of the clinical end points within the first 30 days.
Statistical analysis. The primary end points were analyzed
on an intention-to-treat basis. All values were expressed in
mean  SD.
RESULTS
Table 1 summarizes the patient clinical and angiographic
characteristics. The mean age of the patients was 68  8
years (range 51 to 85 years, 11 patients (7%) were 80
years). Seventy-seven patients (48%) had symptoms attrib-
utable to the treated artery within the three months before the
procedure. Of these, 61% had transient ischemic attacks, 23%
had stroke and 16% had amaurosis fugax. One patient was
treated using the filter system after he developed intolerance
symptoms during CAS with the distal-balloon protection.
Immediate outcome. Angiographic success was achieved
in 162 (99%) of the patients. Successful filter placement and
Figure 2. Carotid angiogram demonstrating flow preservation during carotid artery stenting with the filter protection system. (A) Preprocedural angiogram
showing a high-grade stenosis of the internal carotid artery. (B) The filter (the bottom two arrows) is positioned distal to the lesion. In this case a “buddy
wire” (the white arrow) was required to facilitate filter placement. (C) Carotid angiogram demonstrating flow through the filter (arrows). (D) Final
angiography: the stented site is widely patent.
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retrieval was achieved in 154 (94%) of the procedures. An
additional maneuver, such as a gentle predilation (using a
2-mm diameter balloon) and/or a “buddy wire” placement,
was necessary in 12 (8%) of the cases to facilitate the filter
placement. In these cases, high-grade lesions and/or severe
distal vessel tortuousity made the initial attempt unsuccess-
ful. Failure to place the filter occurred in eight cases (5%)
because of inability of the device to cross-sever stenoses with
tortuous distal anatomy despite additional maneuvers (bud-
dy wire and predilation) in two cases. The procedure was
completed with no protection in five patients and with an
alternative protection system in three; distal balloon protec-
tion (GuardWire, Percusurge Inc., Sunnyville, California)
in two patients, and a different filter protection device
(Angioguard, Cordis Inc., Miami, Florida) was negotiated
through the lesion in one patient after an additional balloon
dilation. Preserved flow through the ICA was angiographi-
cally documented in all of the procedures where the filter
was successfully placed. There was no device failure follow-
ing deployment, and all filters were successfully retrieved in
a completely collapsed condition. Macroscopically visible
particles were retrieved in 54 (35%) of the filters. Pathohis-
tologic analysis of the filter contents was performed in a
subset of 11 consecutive patients. This revealed multiple
debris (mean number of particles per filter was 12, range 0
to 41) that included fibrin, cholesterol clefts, organized
thrombi and red and white blood cell aggregates.
Nonflow-limiting spasm that resolved after removal of
the filter (with/without intravascular nitroglycerin) occurred
in five cases (3%). Flow-limiting spasm at the filter site
occurred in three patients (2%). This resolved completely
with the filter removal in one patient, by advancing the filter
few millimeters in one, and by intravascular nitroglycerin
administration in the third patient. All three procedures
were successfully completed with filter protection with no
associated clinical sequelae. There were no vascular dissections.
There were two procedural minor strokes (1%). One
patient developed blurred vision during a CAS procedure in
which the filter placement was unsuccessful. The interven-
tion was successfully completed without distal protection.
The second patient, a known case of von Willebrand’s
disease whose aspirin had been withheld on the advice of the
hematologist, developed dysphasia immediately following
successful filter retrieval. Both patients recovered completely
within 48 h. Of the 154 patients in whom the filter was
successfully deployed, there was one embolic neurologic
event (0.6%).
30-day outcome. On an intention-to-treat basis, the over-
all combined rate of all strokes and deaths at 30 days was 2%
(four events). These include the two procedural minor
strokes and two deaths. One patient suffered prolonged
brady/tachyarrhythmia following a control arch aortogram,
and a temporary transvenous pacer was placed before stent-
ing and was removed following successful intervention.
Subsequently, the patient developed an asystolic cardiac
arrest and she could not be resuscitated. Autopsy demon-
strated a perforated right ventricle with hemopericardium,
and fatal arrhythmias were given as the cause of death. A
second patient developed massive ipsilateral intraventricu-
lar/subarachnoidal hemorrhage four days following an un-
complicated CAS and died within 24 h from the onset. This
constituted the only neurologic death and was thought to be
due to reperfusion injury. All the remaining patients were
asymptomatic, with no neurologic events or myocardial
infarctions.
DISCUSSION
Carotid artery stenting without distal protection has been
associated with embolic minor stroke rates of 2% to 5% and
major stroke rates of 1% to 1.5% (2–4). In the largest report
of CAS, a multicenter registry by Wholey et al. (8) that
included 5,210 patients, the rates of minor and major
embolic strokes were 2.7% and 1.5%, respectively. Distal
protection has the potential to reduce the risk of emboliza-
tion and enhance the safety of CAS. Preliminary results of
a multicenter trial of CAS using the distal balloon protec-
tion have already shown a favorably low rate of embolic
events (9). Moreover, the ability of the distal balloon
protection to reduce the microembolic load has been dem-
onstrated (10).
The present study demonstrates that the application of a
filter protection system during CAS is feasible and safe. The
risk of atheroembolic complications in patients who had
successful filter placement appears to be favorably low and
notable for the absence of major embolic events. This series
represent the largest experience with a single-design filter
system during CAS, and it confirms the results of two prior
smaller series that evaluated various filter designs during
CAS. Parodi et al. (11) reported the successful application
of an umbrella-shaped filter system during CAS in six
patients with no complications. In a recent report, Reimers
et al. (12) reported no neurologic events during CAS using
various filter designs in a series of 84 patients. The ability of
the NeuroShield filter system to capture embolic particles
during the carotid intervention has been demonstrated in an
ex vivo human carotid artery model (13). In the current
study, macroscopically visible particles were detected in 30%
Table 1. Clinical and Angiographic Characteristics
Age (yrs) (mean  SD) 68  8
Age 80 yrs 11 (7%)
Men (n, %) 28 (87%)




Coronary artery disease 21 (54%)
Prior ipsilateral CEA 13 (8%)
Stenosis severity (mean  SD) 82  9%
Lesion length (mm) (mean  SD) 12  6
Contralateral ICA stenosis of 50% 49 (30%)
Contralateral ICA occlusion (n, %) 18 (11%)
CEA  carotid endarterectomy; ICA  internal carotid artery.
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of the filters (Fig. 3), clinically confirming the prior ex vivo
observation. Moreover, the retrieval of these particles in the
filters provides further clinical evidence of the particulate
matter release during CAS.
Embolic profile during CAS. The majority of CAS-
associated neurologic events occur during the procedure, less
commonly within the immediate 2 to 4 h following the
intervention, and rarely thereafter. Transcranial Doppler
studies have shown that stent deployment, predilation and
postdilation are the most emboligenic phases of the unpro-
tected CAS procedure, and that the risk of embolization
after CAS is completed is very low (10,14). Gensori et al.
(14), using TCD, reported a very low emboligenic potential
in a group of patients within the 24 h following CAS.
Therefore, it is intuitive that the successful application of
any protection strategy during balloon dilations and stent
deployment will result in significant reduction in the risk of
embolic neurologic events during CAS.
Distal protection strategies. Two additional approaches
for distal protection during CAS are under evaluation (6).
The first involves the use of a distal balloon that interrupts
flow though the ICA during intervention. The proximal
blood column, potentially containing embolic material, is
then aspirated before re-establishing the blood flow. The
second approach involves reversing the flow within the ICA.
This is achieved by occluding the CCA, diverting the blood
into the ECA or simultaneously occluding the ipsilateral
CCA and the ECA and diverting the blood into the guiding
catheter that is externally connected to the contralateral
femoral vein. Preliminary experience has shown that all of
these strategies are effective in capturing embolic matter.
However, each of these strategies has its inherent advan-
tages and limitations. The utility of any distal protection
system in the individual patient depends on the lesion
anatomy, the adequacy of collateral circulation, the ease of
use and, most importantly, the efficacy in reducing the risk
of embolic events. Although the filter protection offers the
advantage of a constant cerebral perfusion during CAS,
allowing more time for careful and precise intervention,
microscopic particles smaller than the size of the filter pores
(100 m) may not be captured. The clinical significance
of these particles, however, is uncertain (15). On the other
hand, although both balloon occlusion systems are more
applicable in severe lesions and tortuous vessels, intolerance
may occur rapidly in 5% to 10% of the patients who have
poor collateral blood supply due to incomplete circle of
Willis (4). Confirming the early observation, the current
series demonstrates that following successful placement, the
flow through the filter is preserved and that the filter system
is well tolerated. The crossing profile of the Generation-II
system used in this study made it difficult to cross high-
grade obstruction and/or tortuous anatomy, resulting in 5%
failed filter placements in this series. Recent experience with
the new Generation-III (authors’ personal experience) has
shown that this is more applicable in the tortuous anatomy.
Compared with Generation-II, the new system has a lower
profile and over-the-wire design with a free (nonmounted)
filter. Using this system, the lesion is first crossed using a bare
0.014 178 guidewire. The filter is then delivered and retrieved
over the wire in a similar fashion to the older version.
Future directions. The introduction of distal protection
into the CAS procedure has set the stage for a randomized
comparison of CAS with the traditional surgical treatment
of carotid obstructions, such as CEA (16). Several trials are
being commenced (16). The largest is the Carotid Revas-
cularization Endarterectomy vs. Stenting Trial (CREST), a
randomized controlled trial of CEA versus CAS with filter
protection in the symptomatic patients with extracranial
carotid internal carotid stenosis (16). A second study is the
Carotid Revascularization with Endarterectomy or Stenting
Systems, evaluating CAS with distal protection in asymp-
tomatic patients as well as those patients excluded from
CREST. These and other ongoing trials will further define
the role of CAS in stroke prevention.
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